News | May 15, 2026
Lilly and UNICEF launch $50M push to reach 30 million children with life-saving health care
The target reach is of more than 30 million young people and caregivers across 21 countries
The target reach is of more than 30 million young people and caregivers across 21 countries
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
The clinical study in France evaluated the safety and feasibility of Robocath’s robotic-assisted coronary intervention platform across complex cardiac cases.
NEJM study shows strong protection across strains
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The formulation contains 0.075% Capsaicin, a clinically proven ingredient along with menthol, camphor and eucalyptus oil
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
New Centre of Excellence at Electronic City campus to offer specialised care in epilepsy, cerebrovascular disorders, neurointervention, skull base and spine surgery
Subscribe To Our Newsletter & Stay Updated
